Associated Papers
Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1.
Aly SM et al.
Forensic Science International. Genetics, 2025
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components.
Turner RM et al.
Journal of Clinical Medicine, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics.
López-Fernández LA
Journal of Personalized Medicine, 2018
Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype.
Fattah S et al.
Pharmaceutical Research, 2017
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E et al.
International Journal of Molecular Sciences, 2017
Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.
Oh ES et al.
Drug Metabolism and Pharmacokinetics, 2013
ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation.
Shuker N et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs.
Grover S et al.
Pharmacogenetics and Genomics, 2012
Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2).
Megaraj V et al.
Pharmacogenetics and Genomics, 2011
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.
Sadee W et al.
Clinical Pharmacology and Therapeutics, 2011
Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function.
Laechelt S et al.
The Pharmacogenomics Journal, 2011
Regulation of hepatic ABCC transporters by xenobiotics and in disease states.
Gu X et al.
Drug Metabolism Reviews, 2010
Transporter pharmacogenetics and statin toxicity.
Niemi M
Clinical Pharmacology and Therapeutics, 2010
Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms.
Ide T et al.
Journal of Clinical Pharmacology, 2009
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.
Haenisch S et al.
Pharmacogenetics and Genomics, 2008
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
Fanta S et al.
Pharmacogenetics and Genomics, 2008
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT et al.
Pharmaceutical Research, 2007
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Niemi M et al.
Pharmacogenetics and Genomics, 2006
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M et al.
Clinical Pharmacology and Therapeutics, 2006